You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾德生物(300685.SZ)與日本衞材公司達成靶向藥物臨牀研究合作
格隆匯 11-22 15:53

格隆匯11月22日丨艾德生物(300685.SZ)公佈,近日,公司EISAI CO., LTD.(日本衞材公司)簽署了合作協議公司自主研發的伴隨診斷產品日本衞材公司在研膽管癌靶向藥物中國、日本臨牀上展開合作

EISAI CO., LTD.是研發型製藥企業,總部設於日本。致力於提供填補臨牀需求空白的創新產品以實現“關心人類健康”(hhc)理念,尤其聚焦神經病學及腫瘤學領域。

在腫瘤伴隨診斷領域,公司嚴守國家法律和行業規範,構建了完善的、基於多技術平台的基因檢測整體解決方案。此前,公司ROS1基因融合檢測試劑盒助力輝瑞公司靶向藥物克唑替尼(Xalkori)用於一線治療ROS1融合基因陽性患者的亞太臨牀研究取得成功,獲得日本、韓國、中國台灣醫療器械註冊證,並進日本、韓國醫保。公司“艾惠健®”和“維惠健®產品正作為伴隨診斷助力LOXO ONCOLOGY, INC.(禮來製藥子公司)靶向藥物LOXO-292亞洲臨牀研究(詳見公司於2019624日披露的《關於與LOXO ONCOLOGY,INC.(禮來製藥子公司)達成靶向藥物臨牀研究合作的公告》此次公司與日本衞材公司在其新興靶點的靶向藥物中國、日本臨牀上達成合作是對艾德品牌和產品的信任和肯定有利於進一步增強公司亞洲市場的競爭力,對公司未來的發展將產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account